The Institute for Clinical and Economic Review posted its Final Evidence Report and Report-at-a-Glance on AbbVie’s elagolix for pain associated with endometriosis.
According to a press release, the report was reviewed during a July meeting of the New England Comparative Effectiveness Public Advisory Council. The council found insufficient evidence to conclude elagolix “offers a net health benefit compared to no treatment.”
“While elagolix appears to offer short-term clinical benefits in terms of reduced pain and improved quality of life for women living with endometriosis, evidence is not yet sufficient to rule out the possibility that this therapy may pose long-term safety risks for patients,” ICER CSO Dan Ollendorf said in a statement.
To read the Final Evidence Report, click here.